Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

Gilead Benefit Helps Employees Navigate Cancer Care

Accesswire July 1, 2024

Gilead's Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention

Business Wire June 20, 2024

Gilead and Kite Pharma Celebrates Pride Month

Accesswire June 19, 2024

New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment

Business Wire June 14, 2024

How Luciana Preger Is Helping Advance Gilead's Work in Oncology

Accesswire June 12, 2024

Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA

Business Wire June 6, 2024

Gilead Sciences: Preserving Fertility in the Face of a Cancer Diagnosis

Accesswire June 5, 2024

Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis

Business Wire June 5, 2024

Kite's Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Business Wire June 3, 2024

Encouraging New Data Presented on Kite's Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma

Business Wire June 3, 2024

Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer

Business Wire June 2, 2024

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers

Business Wire June 1, 2024

EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024

Business Wire May 31, 2024

Gilead Provides Update on Phase 3 TROPiCS-04 Study

Business Wire May 30, 2024

Gilead Sciences Partners With White House for Early Cancer Detection Program "Biden Cancer Moonshot"

Accesswire May 28, 2024

Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024

Business Wire May 22, 2024

Gilead Sciences Hosts Inaugural Global Health Equity Summit

Accesswire May 21, 2024

Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis

Business Wire May 18, 2024

Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy

Business Wire May 14, 2024

Gilead Sciences: Native Health Navigator Program Connects Tribes to Cancer Care

Accesswire May 14, 2024